The Company focuses its efforts on cardiovascular diseases, neurological diseases, and oncology. Catalent has a wide range of products, including cardiovascular drugs, anticancer agents, anti-infectives, and anti-inflammatory agents. The Company has critical products in the cardiovascular space, such as Torcetrapib, a drug that addresses congenital heart diseases.
Torcetrapib is an investigational drug currently in clinical trials to treat patients with HF and Tachycardia-Heart Rate Increase. Other cardiovascular products include the anti-ischemic drug AR-A01, an anti-oxidant-derived pro-drug to prevent early and late atherosclerosis, and Orgalutran, a device for treating epilepsy.